Table 2.
Enrichment analysis of the second trimester group
| Pathway associated metabolite sets | Enriched compounds | Total | Hits | Raw p | Holm p | FDR |
|---|---|---|---|---|---|---|
| Alpha linolenic acid and linoleic acid metabolism | Linoleic acid; alpha-linolenic acid; docosahexaenoic acid; adrenic acid; 8,11,14-eicosatrienoic acid | 19 | 5 | 0.000693 | 0.0679 | 0.0679 |
| Beta oxidation of very long chain fatty acids |
L-carnitine; L-acetylcarnitine; Caprylic acid |
17 | 3 | 0.0292 | 1 | 1 |
| Valine-leucine-isoleucine degradation |
Alpha-ketoisovaleric acid; L-Valine; L-Isoleucine;3-Methyl-2-oxovaleric acid; L-Leucine; Ketoleucine; |
60 | 6 | 0.0314 | 1 | 1 |
Pathway associated metabolite sets with p value < 0.05 are shown in the table. Total means total number of metabolites in the metabolite set; Hits mean number of metabolites from GDM patients in the metabolite set; Raw p refers to original p value in the enrichment analysis; Holm p refers to adjusted raw p value by Holm-Bonferroni method; FDR is the false discovery rate